Chiusura precedente | 0,0750 |
Aperto | 0,0730 |
Denaro | 0,2100 x 800 |
Lettera | 0,2050 x 800 |
Min-Max giorno | 0,0730 - 0,0800 |
Intervallo di 52 settimane | 0,0520 - 1,2990 |
Volume | |
Media Volume | 8.563.675 |
Capitalizzazione | 3,17M |
Beta (5 anni mensile) | 1,17 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -2,5000 |
Prossima data utili | 28 mar 2024 - 01 apr 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 5,50 |
SAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that, as part of its ongoing efforts to lower operating expenses, the Company has entered into an agreement to terminate its lease agreement pertaining to the Company's headquarters in San Carlos, CA, whic
Suspending development of ATRC-101 Cost-saving measures include 40% workforce reduction Focusing on advancing earlier stage ADC candidates and preserving discovery capabilities SAN CARLOS, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the sec
Clinical activity observed in multiple tumor types; longer progression-free survival observed in patients with high target expression; ATRC-101 continues to be well-tolerated Phase 2 go/no-go decisions for ATRC-101 expected by end-of-year SAN CARLOS, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human